MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven clinical trial for KRAS-variant positive HPV-positive head and neck cancer patients (HNSCC). The clinical trial will randomly group 70 patients to receive the current standard of care (radiation plus cisplatin) […]
Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news. Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and […]